SU770196A1 - Method for preparing inactivated vaccine against rabies of animals - Google Patents

Abstract

METHOD OF MANUFACTURING INLASTIVATED VACCINES AGAINST ANIMAL BEHINERY, including the design of shredding the cerebral tissue of sheep infected with a fixed rabies virus, a maker AIKI, inactivating the viral suspension, combining it with the drying medium, followed by the maker, the maker of the viral suspension, its connection with the drying medium, followed by the maker of the maker of the viral suspension, its connection with the drying medium, followed by the maker of the maker of the viral suspension, its composition with the drying medium, followed by the maker of the maker of the virus suspension, combined with the drying medium, followed by the maker, and the maker of the viral suspension, combined with the drying medium, followed by packaging, and the maker of the maker of the viral suspension, combined with the drying medium, followed by the maker of the maker of the virus suspension, combined with the drying medium, followed by the maker, and the maker of the virus suspension, combined with the drying medium, followed by the maker, and the maker of the virus suspension. that, in order to increase the immunogenicity of the vaccine and its harmlessness, the inactivation of the virus suspension is carried out with a 20-21% solution of ethanol at 30-3lc for 12-14 days. with S (L

Description

; About l

This invention relates to the field of veterinary virology, in particular, to methods for producing inactivated rabies vaccines of animals used for therapeutic and prophylactic vaccine against this disease.

A known method of manufacturing an inactivated rabies vaccine of animals using an inactivator hydroxylamine C H. This method is no longer used in the practice of making this vaccine, since the vaccine is ready to contain an inactivator that is toxic to animals or its chemical compound.

There is also known a method for the manufacture of an inactivated animal rabies vaccine, including shredding of the brain tissue of sheep infected with a fixed rabies virus, a sheep strain of GNI, inactivating the virus suspension, its connection with the drying medium, followed by packaging the semi-finished product and its lyophilization C2.

The disadvantage of this method is that the vaccine obtained is less immunogenic, has a residual virus up to LD / 0.03 m and causes post-vaccination complications in cattle and decorative breeds of dogs. Phenol as an inactivator is a toxic substance. Release of a non-sterile drug is allowed.

The aim of the invention is to increase the immunogenicity of the vaccine and its safety.

This is achieved by the fact that the inactivation of the virus suspension is carried out with a 20-21% solution of ethanol at 30-31 0 for 12-14 days.

Example. To produce a series of inactivated dry anti-infectious ethanol vaccine, infect sheep in the brain with a virus, rabies in a dose of p, 5 ml with a working dilution of 1: 500 according to the instructions.

A 20% solution of ethiol is preliminarily prepared at the rate of: 1 h. 9§ alcohol for 4 hours of sterile saline. 300350 ml of a 20% ethanol solution are added to a one-liter glass jar and weighed 4

Sheep with typical clinical signs of laboratory rabies and a period of. 4 to 5 days from the moment of infection, exsanguinate, then separate the head, and remove the brain, which is placed. in a prepared jar with 20% ethanol solution on the physiological. solution pH 7.2-7.4. Pre-tejjbHo do seeding on bacteriological nutrient medium (tubes) and watch them when incubated in a thermostat (for 10 days.

Brain tissue is removed from the cans and placed in a colloid mill and crushed at ZOOP rpm for 5 minutes with a gap of 0.05 cm, 20% ethanol solution is added based on 30 g of brain tissue 70 ml of 20% solution ethanol, i.e. receive a suspension of 30% of the brain tissue. The bottle with the semi-finished product is placed in a thermostat at 30 ° C for 12 days, mixing the suspension 3-4 times a day.

After the inactivation period has expired, a drying medium for 2 hours, a suspension for 1 hour, a drying medium (composition: 100 ml of bidistilled water, 22.5 g of sucrose and 3 g of gelatin) are added to the suspension. The final concentration of brain tissue in the liquid semi-finished product of the vaccine is 20%. The vaccine is filled into penicillin vials of 12 ml and subjected to sublimation vusushiviiyu in the usual way. The finished vaccine is controlled for sterility, harmlessness, absence of residual virus, chickens, and solubility by conventional means.

The vaccine obtained by the proposed method consists of the following components: virus-containing tissue of the brain of sheep with a virus titer not lower than LD0 / 0.03 ml in 15-17% solution of ethanol 20-25, stabilizer 75-80.

The obtained data on the verification of the obtained production batches of the vaccine against rabies by the proposed method make it possible to judge that these manufactured series, inactivated by ethanol, were sterile, avirulent, harmless to various laboratory and farm animals, and also had pronounced and unogenous properties that reported , immunized animals, and immunity applied by the 14th day, which lasts until the 98th day (observation period).

The vaccine is suitable for mass immunization of animals of all species with both preventive and therapeutic purposes.

The vaccine is administered subcutaneously and intramuscularly with KOftMOM for wild animals. Doses for intramuscular administration, ml: dogs 2-3, cattle 5shp m 9-10, cats 1-1.5, sheep 3-3.5 pigs 9-10, fur-bearing animals 1.5-2,, donkeys 4.5-5 ..

The economic effect of vaccination of animals is the sum of

37701964

averting the spread of the disease, animals, and reducing cases of possible recovery of disadvantaged items, a person’s contract with animals, and creating an immune population among street rabies pathogens.

Claims (1)

METHOD FOR MANUFACTURING AN INACTIVATED ANTI-ANIMAL VACCINE VACCINE, including crushing the brain tissue of sheep infected with a fixed rabies virus, a strain of sheep’s GNI, inactivation of the viral suspension, its combination with a drying medium, followed by packaging of the semi-finished product and its lyophil the fact that, in order to increase the immunogenicity of the vaccine and its harmlessness, inactivation of the viral suspension is carried out with a 20-21% solution of ethanol at 30-31 ° C for 12-14 days. <3